Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.44 |
| ▸ | PAK3 | O75914 | 1/20 | 0.43 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805021 | 0.91 | PAK1 (0.43) | PAK1TRPV1PDGFRB | |
| SCHEMBL2802923 | 0.87 | TRPV1 (0.58) | PAK1TRPV1PDGFRBKDRFLT3 | |
| SCHEMBL2803952 | 0.84 | TRPV1 (0.56) | PAK1TRPV1FLT3 | |
| SCHEMBL2805093 | 0.81 | PAK1 (0.44) | PAK1TRPV1 | |
| SCHEMBL2806213 | 0.80 | FGFR2 (0.49) | PAK1TRPV1PDGFRBKDRFLT3 | |
| SCHEMBL2802586 | 0.80 | FLT3 (0.47) | PAK1TRPV1FLT3 | |
| SCHEMBL2486602 | 0.79 | RAB9A (0.55) | PAK1TRPV1PDGFRB | |
| SCHEMBL2804209 | 0.79 | TRPV1 (0.54) | PAK1TRPV1 | |
| SCHEMBL2803705 | 0.79 | MAPT (0.51) | PAK1TRPV1 | |
| SCHEMBL2803935 | 0.78 | NPC1 (0.58) | PAK1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263610-B2 | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds | ARQULE, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263610-B2 | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds | ARQULE, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263610-B2 | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds | ARQULE, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100239526-A1 | SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239526-A1 | SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239526-A1 | SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010078427-A1 | SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239526-A1 | SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS | NQO1, IDH3B, IDH1 | PAK1 717/4885S1PR2 3491/4885PAK3 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.